Comparable cancer-specific survival but diminished adjuvant chemotherapy benefit in early-onset gastric cancer: A propensity score-matched analysis of SEER and Chinese cohorts.
Abstract
Background
The incidence of early-onset gastric cancer (EOGC) is rising globally, whether its distinct clinicopathological profile translates into differential prognosis or chemotherapy efficacy remains contentious.
Methods
We analyzed patients with stage Ⅰ-Ⅲ gastric adenocarcinoma undergoing curative gastrectomy from the Surveillance, Epidemiology, and End Results (SEER) database and Xijing Hospital (2010-2015). Cox regression was applied to identify independent prognostic factors. Propensity score matching (PSM) was performed to balance baseline characteristics between EOGC (age ≤45 years) and late-onset gastric cancer (LOGC; age >45 years). PSM was reperformed when evaluating adjuvant chemotherapy efficacy for stage Ⅱ-Ⅲ disease. Overall survival (OS) and cancer-specific survival (CSS) were compared using Kaplan-Meier and log-rank tests.
Results
5155 patients from SEER and 2337 from the Chinese cohort were included. Before matching, EOGC was characterized by more female patients, poorer differentiation, and higher adjuvant chemotherapy uptake. Multivariate analysis confirmed chemotherapy as an independent protective factor for OS only in LOGC. After PSM, CSS was comparable between EOGC and LOGC in either cohort (all P > 0.05). Notably, in stage Ⅱ-Ⅲ disease, adjuvant chemotherapy significantly improved CSS in LOGC (P < 0.001 for both cohorts) but conferred no significant benefit in EOGC (SEER: P = 0.98; China: P = 0.10).
Conclusion
After baseline adjustment, EOGC demonstrates CSS comparable to that of LOGC. However, adjuvant chemotherapy does not improve CSS in stage Ⅱ-Ⅲ EOGC, calling into question the uniform chemotherapy strategy for young patients. Integrated molecular profiling is warranted to guide systemic therapy in EOGC.